Generic Name: Trientine Hydrochloride
Brand Name: MAR-Trientine
Manufacturer: Marcan Pharmaceuticals Inc.
Therapeutic Area: Wilson's Disease
Indications: MAR-Trientine (trientine hydrochloride) is indicated for the treatment of patients with Wilson's Disease who are intolerant to penicillamine. MAR-Trientine should only be initiated by physicians experienced in the management of Wilson’s Disease.
Manufacturer Requested Reimbursement Criteria1: MAR-Trientine (trientine hydrochloride) to be reimbursed for the treatment of patients with Wilson's Disease who are intolerant to penicillamine.
Submission Type: Initial
NOC Status at Filing: Post NOC
Project Status: Active
Companion Diagnostics: No
Fee Schedule: Schedule A
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
|Call for patient/clinician input open||March 18, 2021|
|Call for patient/clinician input closed||May 07, 2021|
- Patient input submission received from the Canadian Liver Foundation
|Submission received||April 19, 2021|
|Submission accepted||May 03, 2021|
|Review initiated||May 04, 2021|
|Draft CADTH review report(s) provided to sponsor for comment||July 19, 2021|
|Deadline for sponsors comments||July 28, 2021|
|CADTH responses on draft review report(s) provided to sponsor||September 10, 2021|
|Expert committee meeting (initial)||September 22, 2021|
|Draft recommendation issued to sponsor||October 04, 2021|
October 06, 2021